Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revusiran in TTR-mediated Familial Amyloidotic Cardiomyopathy
NCT02319005Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Dec 2014
- Primary completion
- Mar 2017
- Modality
- Gene Editing, Gene Silencing, Conjugated siRNA
- Countries
- 9
01
Overview
A Phase 3 trial of revusiran in familial amyloidotic cardiomyopathy (hATTR-CM), sponsored by Alnylam Pharmaceuticals. Started Dec 2014; status: completed.
02
Drugs
revusiran
03
Conditions
familial amyloidotic cardiomyopathy (hATTR-CM)
Beyond the preview
Go deeper on NCT02319005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319005.